Significance Statement {#s5}
======================

Psychotherapeutic interventions such as mindfulness-based therapy or TAU may influence inflammatory responses that contribute to psychological health. In the present study, we investigated the role of MIF and its regulating miR-451a and found that MIF was significantly decreased after psychotherapeutic intervention. Another important finding is that MIF was inversely related to plasma miR-451a levels in patients with depression, anxiety, or stress and adjustment disorders. For the first time, it is shown that MIF and miR-451a may have a role in patients with psychiatric disorders.

Introduction {#s6}
============

Macrophage migration inhibitory factor (MIF) is one of the first cytokine-like proteins that was discovered more than 50 years ago (B. R. [@CIT0010]; [@CIT0020]). MIF was named for its ability to recruit macrophages to sites of inflammation and prevent their random migration. It is synthesized by T- and B-lymphocytes, monocytes, macrophages, dendritic cells, neutrophils, eosinophils, mast cells, and basophils. MIF is widely distributed in tissues. High levels of MIF expression are noted in the endocrine system, especially in the organs that are involved in stress responses, for example, hypothalamus, pituitary, and adrenal glands ([@CIT0059]; [@CIT0014]; [@CIT0023]). MIF has pleiotropic effects on inflammation, chemotaxis, cell survival, and proliferation that act as a regulator of innate immune and inflammatory responses ([@CIT0039]; [@CIT0014]; [@CIT0007]; [@CIT0047]; J. [@CIT0011]). Inducers for MIF releasing include microbial products such as lipopolysaccharides and proinflammatory cytokines. Once released, MIF acts in an autocrine or paracrine fashion to induce production of proinflammatory cytokines ([@CIT0015]; [@CIT0013]; [@CIT0014]; J. [@CIT0011]). MIF also interferes with the antiinflammatory activity of glucocorticoids at a transcriptional and posttranscriptional level ([@CIT0023]). Circulating MIF is increased during episodes of inflammation, infection, and stress ([@CIT0006]; [@CIT0005]; [@CIT0014]).

MicroRNAs (miRNAs) are a class of small (21-23-nucleotide), noncoding, single-stranded RNAs that inhibit gene expression by promoting messenger-RNA (mRNA) degradation or inhibiting translation ([@CIT0001]). They influence a variety of physiological cell processes during development and tissue homeostasis by regulating the expression of around 90% of all human genes ([@CIT0038]). Numerous miRNAs have been recently detected in several body fluids, including serum, plasma, and cerebrospinal fluid ([@CIT0067]). Blood cells extensively contact plasma; thus they can be the major contributors to extracellular miRNA content in plasma ([@CIT0045]; [@CIT0057]; [@CIT0034]), which can be derived under different conditions ([@CIT0056]). The biological significance of secreted miRNAs remains to be determined ([@CIT0057]). One explanation is that cells secrete miRNAs after reducing the target mRNA expression, while the unused miRNA is redundant ([@CIT0051]). On the other hand, the presence of extracellular miRNAs involves cell-to-cell communication via selective miRNA export system ([@CIT0068]; [@CIT0058]; [@CIT0055]). Several miRNAs targeting MIF were identified in silico using bioinformatic programs such as TargetScan and miRSystem (version 20120229; and miRDB, version 4.0) ([@CIT0033]). MIF was identified as a target of miR-451a and this was confirmed by multiple studies. For example, miR-451a can directly target MIF and downregulate its expression and can lead to decreased cell proliferation, colony formation, cell migration and invasion in vitro, suppress xenograft tumor growth in vivo, and modulate epithelial cell survival ([@CIT0003]; N. [@CIT0032]; [@CIT0025]; [@CIT0054]; G. [@CIT0031]). Furthermore, miR-451 is widely expressed in different cells, such as red blood cells, white blood cells, platelet samples, and serum/plasma (K. [@CIT0063]). However, the relation between circulating miR-451a and MIF is largely unknown.

Dysregulation of the immune system and inflammatory response has been linked to the pathophysiology of certain psychiatric disorders, such as depression ([@CIT0027]). For example, the role of MIF in the pathobiology of depression has been investigated in different ways (J. [@CIT0011]). MIF is expressed in the brain especially in the areas concerning behavioral symptoms of depression and anxiety ([@CIT0019]). Behaviorally, genetic deletion of MIF has resulted in increased anxiety- and depression-like behaviors, and the role of MIF in mediating the antidepressant action of exercise has been found ([@CIT0019]; [@CIT0040]). In blood, the association between MIF and mood disorders may be the opposite. Previous studies have shown that blood MIF levels are increased in subjects with mild to moderate depression, major depression, and other mood disorders ([@CIT0004]; [@CIT0026]; [@CIT0042]; J. [@CIT0011]). Treatment with antidepressants can reduce the blood levels of MIF ([@CIT0017]). MIF does not, however, cross the blood brain barrier ([@CIT0002]), so the blood level of MIF may be a consequence of different albeit related processes of depression (J. [@CIT0011]).

Recently, the role of miRNAs in the development of depression and in antidepressant treatment has gained significant attention. Studies conducted on postmortem brains from subjects who suffered from depression and subsequently committed suicide showed alterations in 29 miRNAs compared with nonpsychiatric control subjects ([@CIT0049]). Several studies have reported on the role of miR-124-3p in depression. MiR-124-3p may be used as a biomarker for diagnosis and antidepressant treatment response, because miR-124-3p is a target of antidepressants and shows similar changes in the blood and brain of patients suffering with depression ([@CIT0021]; [@CIT0046]). MiR-135a has also been found to be lower in the blood of patients with depression and was increased after treatment with antidepressants ([@CIT0029]). To our knowledge, the role of miR-451a in psychiatric disorders has not been fully investigated ([@CIT0016]; [@CIT0061]). One research group found that treatment with antidepressant could reverse the stress-induced change of miR-451 expression in rat hippocampus ([@CIT0043]). However, it is not known whether psychotherapeutic interventions can affect plasma levels of MIF or miR-451a in patients with psychiatric disorders. We therefore aimed to examine whether psychotherapeutic interventions (mindfulness therapy or treatment as usual \[TAU\], mainly cognitive-behavioral therapy \[CBT\]) are associated with MIF or miR-451a levels in patients with psychiatric disorders (depression, anxiety, and stress and adjustment disorders) who have been treated in primary health care. Mindfulness-based therapies and CBT are effective ways of treating depressive disorders and are associated with reductions in proinflammatory processes according to previous research ([@CIT0052]; [@CIT0028]; [@CIT0053]; [@CIT0008]; [@CIT0060]; [@CIT0036]).

Our study population was based on a previously published randomized controlled trial (RCT) conducted by our research group. The study population included patients with depression, anxiety, or stress and adjustment disorders from 16 primary health care centers in Sweden who were treated with mindfulness-based therapy or TAU for 8 weeks ([@CIT0053]). In the present analysis, we analyzed MIF and miR-451a collected in the RCT at baseline and after the 8-week follow-up. Our overall aim was to investigate levels of MIF and its regulating miR-451a in patients with depression, anxiety, or stress and adjustment disorders who underwent mindfulness-based therapy or TAU. We first investigated the potential changes in plasma levels of MIF and miR-451a after 8 weeks of mindfulness-based therapies or TAU in the patients with depression, anxiety, or stress and adjustment disorders. Later we explored the potential association between plasma levels of MIF and miR-451a at baseline and between changes in levels of MIF and miRNA-451a posttreatment. Finally, we investigated whether the possible changes in MIF and miR-451a were associated with the improvement in psychiatric symptoms (assessed using MADRS-S) posttreatment.

Methods {#s7}
=======

Study Subjects and Sample Collection {#s8}
------------------------------------

The study population included 168 patients (age 21--65 years) with depression, anxiety, or stress and adjustment disorders. All the patients were recruited from the 16 primary health care centers that had participated in a randomized controlled trial (RCT) of mindfulness therapy compared with TAU, mainly CBT. A detailed description of the study design is provided in a previous article ([@CIT0053]). Patients were recruited between January 4, 2012 and March 22, 2012 at the 16 primary health care centers in the county of Scania (Skåne in Swedish) in southern Sweden.

Patients who fulfilled the inclusion criteria were included in the study. All clinical diagnoses were made by doctors at the 16 primary health care centers, including one or more of the following ICD-10 psychiatric diagnoses: F32.0, mild depressive episode; F32.1, moderate depressive episode; F32.9, depressive episode, unspecified; F33.0, recurrent depressive disorder, current episode mild; F33.1, recurrent depressive disorder, current episode moderate; F41.0, panic disorder; F41.1, generalized anxiety disorder; F41.2, mixed anxiety and depressive disorder; F41.3, other mixed anxiety disorders; F41.8, other specified anxiety disorders; F41.9, anxiety disorder, unspecified; F43.2, adjustment disorders; F43.8, other reactions to severe stress; and F43.9, reaction to severe stress, unspecified; age 20 to 64 years; ability to speak and read Swedish; and a score of ≥10 on the Patient Health Questionnaire (PHQ)-9 or ≥7 on the Hospital Anxiety and Depression Scale (HADS) or a total score on the Montgomery-Åsberg Depression Rating Scale (MADRS-S) between 13 and 34 (mild to moderate depression). The exclusion criteria were as follows: severe personality disorder, risk of suicide, pregnancy, thyroid disease, current psychotherapy of any kind, and participation in any other psychiatric intervention study. Each patient filled in 3 self-rated questionnaires (above-mentioned PHQ-9, HADS-A/HADS-D, and MADRS-S) at baseline and after 8 weeks of follow-up. The patients received antidepressants and tranquilizers (pharmacotherapy) if deemed necessary. Blood samples were collected at the same time as the assessment of self-rated symptoms before and after treatment. Patients with missing clinical information or poor-quality plasma samples, for example, hemolysis samples, were excluded from our study.

Plasma Collection {#s9}
-----------------

Whole blood (6 mL) was collected from each participant in EDTA tubes. Blood samples were centrifuged at 2000 g for 10 minutes at 4°C, and the plasma was then aliquoted and stored at -80°C before further processing. Blood samples were processed and the plasma was frozen within 8 hours of collection ([@CIT0024]).

Detection of MIF and miRNA in Plasma Samples {#s10}
--------------------------------------------

Plasma MIF levels were determined using the bead-based multiplex assay for the Luminex platform (R&D Systems Inc) based on the manufacturer's instructions. To summarize, 80 µL of plasma was diluted 1:2 in the dilution buffer and then incubated with antibody-coated magnetic bead. Protein levels were measured using the Bio-Plex suspension array system and data were analyzed with Bio-Plex Manager software (Version 4). Absolute concentrations were calculated from a standard curve generated from 8 serially diluted standards provided in the kit. The intra- and inter assay CV were 3.8% and 4.4%, respectively. Duplicate samples were assayed and all results were reported as means.

Plasma miRNA measurement was performed as previously described (X. [@CIT0065], [@CIT0053]). In brief, 50 µL of total RNA was isolated from 200 µL of plasma using the miRNeasy Mini Kit (Qiagen GmbH) according to the manufacturer's protocol, with minor modifications. miRNAs were reverse transcribed using a Universal cDNA Synthesis kit (Exiqon). Quantitative real-time PCR (qPCR) was carried out in 384-well plates using the CFX38 real-time PCR detection system (Bio-Rad Laboratories). At present, there are different methods to detect hemolysis, including low levels, in plasma /serum ([@CIT0009]). ([@CIT0030]; [@CIT0048]). Blondal et al. suggested that the ratio (miR-451a/miR-23a-3p) of red blood cell-enriched miR-451a to miR-23a-3p, the latter not affected by hemolysis, could be used as an indicator of hemolysis. The ratio of miR-451a to miR-23a-3p was found to be the most sensitive method that could detect as little as 0.001% hemolysis in serum. Briefly, miR-451a/miR-23a-3p ratios of \<5, 5--7, and \>7 indicate low, mild, or high risk of hemolysis. Both miR-451a and miR-23a-3p were measured in all the plasma samples. Samples with a ratio of ≥7 were excluded in the analysis. Our measurements showed that the Ct value for miR-451a was 23.1±0.8 (mean±SD) and the Ct value for miR-23a--3p was 26.3±1.4 in all the patient samples. This indicates that miRNA-451a levels displayed little variation between individuals. There were 6% of samples with a ratio of 5 to 7. For these 6% of samples, the Ct value for miR-451a was 22.7±0.7 (mean±SD) and the Ct value for miR-23a--3p was 28.2±0.9. There were no significant differences in miRNA-451a levels between these 6% of samples and the whole study population. Therefore, we included these 6% in our analysis. At present, no generally accepted standards for normalization of miRNA PCR data have been established. Different methods have been suggested. Some studies have used spike-in oligonucleotides U6 as normalization controls in their study ([@CIT0069]; [@CIT0025]). Nonetheless, these synthetic miRNAs are not incorporated in microvesicles or protein lipid complexes. Therefore, extraction efficiency is not accounted for. Alternatively, endogenous miRNAs that are detectable in all samples show lower variation of expression levels and have been used as internal controls previously ([@CIT0012]; X. [@CIT0066]). In the present study, the Ct values were normalized according to the ∆Ct method with the internal controls miR-425-5p and miR-186-5p. These 2 reference miRNAs were selected based on the screening of miRNA expression using a Serum/Plasma Focus microRNA PCR Panel (Exiqon) comprising 179 LNA microRNA primer sets in the selected 11 samples (X. [@CIT0064]). The geometric mean of 2 or more selected reference genes is more accurate than a single gene for normalization ([@CIT0062]). The normalization stability of these two miRNAs was confirmed in our study with geNorm software ([@CIT0050]) and the result is shown in [supplementary Figure 1](#sup2){ref-type="supplementary-material"}. These 2 miRNAs have also been used as reference miRNAs in previous studies ([@CIT0012]; X. [@CIT0065]; [@CIT0018]). Our measurements showed that the Ct value for miR-186-5p was 29.4±0.9 (mean±SD) and the Ct value for miR-425--5p was 28.3±1.0 in all the patient samples. This indicates that those two reference miRNAs are robust. The relative expression of miR-451a was calculated with miR-425-5p and miR-186-5p using the following equation: ∆Ct=Ct ~miR-425-5p&miR-186-5p\ (geometric\ mean\ of\ two\ miRNAs)~ -- Ct ~miR-451a~. The changes of miRNA level after follow-up, the expression of miRNA at 8 weeks follow-up is compared to expression of the miRNA at baseline. It was calculated with the formula ΔΔCT=∆Ct ~follow-up~ - ∆Ct ~baseline~.

Ethical Considerations {#s11}
----------------------

The study was performed according to the principles of the Declaration of Helsinki. It was reviewed and approved by the Ethics Committee of Lund University, prior to its commencement, on 5 October 2011 (application no. 2011/491). Written informed consent was obtained from all participants.

Statistical Analysis {#s12}
--------------------

Data are presented as mean and SD for age, body mass index (BMI), and baseline miR-451a levels. Median and interquartile range (IQR) were used for baseline MADRS-S and MIF, whereas sex, smoking, and alcohol status and antidepressant and tranquilizer use are presented as numbers and percentages ([Table 1](#T1){ref-type="table"}).

###### 

Characteristics of the Study Population at Baseline (n=168)

  Variables                       Patients (n=168)
  ------------------------------- ------------------
  Age, y                          
   Mean (SD)                      42.2 (11.0)
  Sex, n (%)                      
   Male                           22 (13)
   Female                         146 (87)
  BMI^*a*^                        
   Mean (SD)                      26.9 (5.6)
  Smoking status, n (%)^*b*^      
   Yes                            22 (13.1)
   No                             143 (85.1)
  Alcohol status, n (%)^*c*^      
  Standard size drinks per week   
   ≤1                             144 (85.7)
   \>1                            19 (11.3)
  Antidepressants, n (%)^*d*^     
   Yes                            55 (33)
   No                             97 (58)
  Tranquilizers, n (%)^*e*^       
   Yes                            24 (14)
   No                             121 (72)
  Baseline MADRS-S                
   Median score (IQR)             20 (10)
  Baseline MIF (pg/mL)            
   Median score (IQR)             5398 (4339)
  Baseline miR-451a (ΔCt)         
   Mean (SD)                      5.75 (1.30)

Abbreviations: BMI, body mass index; IQR,interquartile range.

^*a*^9 patients had missing on BMI.

^*b*^3 (1.8%) had missing on smoking status.

^*c*^5 (3%) had missing on alcohol status.

^*d*^16 (9%) had missing on antidepressants.

^*e*^23 (14%) had missing on tranquilizers.

To estimate the change between baseline and the 8-week follow-up, we used the median and IQR for MIF and the mean and SD for miR-451a and tested it with a nonparametric test (Wilcoxon sign-rank test) for MIF and a paired *t* test for miR-451a ([Table 2](#T2){ref-type="table"}).

###### 

MIF and miR-451a (ΔCt) for Patients at Baseline and 8-Week Follow-up (Mindfulness and TAU)

  Variables      Baseline      Follow-up     Difference    *P*-value
  -------------- ------------- ------------- ------------- --------------
  MIF                                                      
  Median (IQR)   5398 (4339)   4561 (3131)   -718 (2797)   \<.0001^*a*^
  miR-451a                                                 
  Mean (SD)      5.75 (1.30)   5.80 (1.32)   0.05 (1.05)   .54^b^

^*a*^Difference tested by Wilcoxon sign-rank test.

^*b*^Difference tested by paired *t* test.

Linear regression models were used to test the association between MIF (transformed with the common logarithm because of a highly skewed distribution) and miR-451a at baseline, both unadjusted and adjusted for potential confounders ([Table 3](#T3){ref-type="table"}). The following potential confounders were considered, age, sex, BMI, smoking, and alcohol status and pharmacotherapy (antidepressants and/or tranquilizers). In addition, the associations between changes in MIF (follow-up levels minus baseline levels) and changes in miR-451a (follow-up levels minus baseline levels) were tested using linear regression and adjusted for the potential confounders ([Table 4](#T4){ref-type="table"}). These results are also shown in a figure format together with a Pearson correlation coefficient (ρ) and a coefficient of determination (R2) ([supplementary Figure 2](#sup3){ref-type="supplementary-material"}).

###### 

Associations Between MIF^*a*^ and miR-451a (ΔCt) and Other Clinical Variables at Baseline (n=168)

                                               Unadjusted /Univariate analysis   Adjusted                                  
  -------------------------------------------- --------------------------------- ---------- --------------- ------- ------ --------------
  miR-451a                                     -0.03                             .02        -0.06; -0.005   -0.04   .008   -0.07; -0.01
  Age                                          0.006                             .001       0.002; 0.009                   
  Sex (female vs male)                         -0.04                             .46        -0.16; 0.07                    
  BMI                                          0.003                             .35        -0.004; 0.01                   
  Smoking status (yes vs no)                   0.12                              .03        0.01; 0.24                     
  Alcohol status (\>1 vs ≤1)                   0.04                              .50        -0.08; 0.17                    
  Pharmacotherapy treatment^*d*^ (yes vs no)   -0.05                             .25        -0.13; 0.03                    

^*a*^MIF was transformed with the common logarithm (log10).

^*b*^Association tested by a linear regression model.

^*c*^Adjusted for age, sex, BMI, smoking and alcohol status, and pharmacotherapy treatment (antidepressants and/or tranquilizers).

^*d*^Antidepressants and/or tranquilizers.

###### 

Associations between the Change in MIF^*a*^ (Follow-Up Level - Baseline Level) and Change in miR-451a (∆∆Ct=∆Ct ~follow-up~-∆Ct ~baseline~)

             Unadjusted   Adjusted                                    
  ---------- ------------ ---------- -------------- ------- --------- --------------
  miR-451a   -0.08        \<.0001    -0.10; -0.05   -0.06   \<.0001   -0.09; -0.03

^*a*^MIF was transformed with the common logarithm (log10).

^*b*^Association tested by a linear regression model.

^*c*^Adjusted for age, sex, BMI, smoking and alcohol status, and pharmacotherapy treatment (antidepressants and/or tranquilizers).

To assess the potential association between MIF/miR-451a and treatment response, we used linear regression analysis to analyze the changes in MIF/miR-451a and the changes in MADRS-S adjusted for MADRS-S at baseline, both unadjusted and adjusted for the potential confounders ([Table 5](#T5){ref-type="table"}). This was also examined by testing the potential difference in changes in MIF (using a T-test) between responders (defined as ≥50 % decrease in MADRS-S after follow-up) ([@CIT0073]) and nonresponders ([supplementary Table 1](#sup1){ref-type="supplementary-material"}). The results from linear regression models for the associations between MADRS-S and MIF and miR-451a levels at both baseline and follow-up are shown in a scatterplot together with a Pearson correlation coefficient (ρ) and a coefficient of determination (R2) ([supplementary Figure 3](#sup4){ref-type="supplementary-material"}).

###### 

Associations between the Change in MIF^*a*^ (Follow-Up Level - Baseline Level)/miR-451a (∆∆Ct=∆Ct ~follow-up~-∆Ct ~baseline~) and the Change in MADRS-S Adjusted for MADRS-S at Baseline

  ----------------------------------------------------------------------------
              Unadjusted   Adjusted                              
  ----------- ------------ ---------- ------------- ------ ----- -------------
  MIF\        2.52         .36        -2.88; 7.93   1.37   .65   -4.56; 7.30
  MADRS-S                                                        

  miR-451a\   0.64         .21        -0.37; 1.65   0.49   .37   -0.58; 1.57
  MADRS-S                                                        
  ----------------------------------------------------------------------------

^*a*^MIF was transformed with the common logarithm (log10).

^*b*^Association tested by a linear regression model.

^*c*^Adjusted for age, sex, BMI, smoking and alcohol status, and pharmacotherapy treatment (antidepressants and/or tranquilizers).

A sensitivity analysis was performed where the period between blood collection and isolation of the samples was also considered in the analysis, but it did not change our results (data not shown). Hence, it was not included in the final models. MiR-451a is enriched in erythrocytes and hemolysis may affect the results. We used a well-known method, the ratio of miR-451a to miR-23a-3p, for detecting hemolysis in plasma/serum. As mentioned in the methods section, samples with a ratio of 7 or more were excluded from the analysis. In total, 6% of the samples with a ratio between 5 and 7 were included in the present study. We also performed an additional analysis where these samples were excluded, but this did not change the results (data not shown).

Statistical analyses were performed by using IBM SPSS Statistics 23 (IBM) and STATA version 14 (StataCorp LP).

Results {#s13}
=======

Patient Characteristics {#s14}
-----------------------

The clinical characteristics of the patients are shown in [Table 1](#T1){ref-type="table"}. The mean age in the whole group (n=168) was 42.2 years (SD=11) and most of these participants were women. The mean BMI was 26.9. Most participants were nonsmokers (85.1%) or low consumers of alcohol. The median scores at baseline indicated mild to moderate symptoms of depression and/or anxiety. After treatment, the median scores decreased, indicating none to mild symptoms (similar results for both HADS-A/HADS-D and PHQ-9, data not shown) ([@CIT0053]).

The Effects of Treatment (Mindfulness-Based Therapy or TAU) on Plasma MIF and miR-451a {#s15}
--------------------------------------------------------------------------------------

[Table 2](#T2){ref-type="table"} shows that the MIF levels decreased significantly after the 8 weeks of treatment (median: 4561, IQR: 3131, pg/mL) compared with the baseline levels (median: 5398, IQR: 4339, pg/mL) (*P*\<.0001). By contrast, miR-451a levels showed a nonsignificant change. A random-intercept linear regression model was used to examine the potential difference in effect between mindfulness and TAU on MIF and miR-451a levels in the patients. This analysis showed no significant difference in patients treated with mindfulness or TAU (data not shown).

The Association Between Plasma MIF and miR-451a in Patients {#s16}
-----------------------------------------------------------

We further investigated the potential role of miR-451a in regulating MIF levels. [Table 3](#T3){ref-type="table"} shows that MIF levels were significantly associated with age and smoking status, with higher age and smoking (yes vs no) associated with higher levels of MIF (β=0.006, *P*=.001 and β=0.12, *P*=.03). Higher BMI and an alcohol consumption of more than one standard size drink were also positively associated to MIF, although not significant. We performed linear regression analysis to assess the potential association between MIF and miR-451a levels at baseline. Unadjusted linear regression revealed that MIF levels at baseline were inversely related to miR-451a levels (β=−0.03, *P*=.02). Results remained significant after adjusting for age, sex, BMI, smoking, and alcohol status and pharmacotherapy (β=−0.04, *P*=.008).

In addition, we investigated the association between changes (follow-up level minus baseline level) in MIF and miR-451a posttreatment. With the linear regression analysis (as shown in [Table 4](#T4){ref-type="table"}), we found that the change in levels of MIF was significantly associated with the change in levels of miR-451a (β=−0.08, *P*\<.0001), although miR-451a showed a nonsignificant change before and after treatment ([Table 2](#T2){ref-type="table"}). These results are also presented in [supplementary Figure 2](#sup3){ref-type="supplementary-material"} (ρ=−0.40 and r^2^=0.16). Adjustment for age, sex, BMI, smoking and alcohol status, and pharmacotherapy did not change the results (β=−0.06, *P*\<.0001).

The Potential Role of MIF/miRNA-451a in the Improvement in Psychiatric Symptoms in Response to the Treatment {#s17}
------------------------------------------------------------------------------------------------------------

Moreover, we performed a linear regression analysis to evaluate the potential association between the changes in MIF/miR-451a and the improvement in psychiatric symptoms in response to the treatment (MADRS-S score). However, there were no significant associations between the change in either MIF or miR-451a and the change in MADRS-S ([Table 5](#T5){ref-type="table"}). Similar results were found for both HADS-A/HADS-D and PHQ-9 (data not shown in tables). This was also investigated by examining the difference in MIF changes between responders (defined as a percentage reduction of ≥50 % in the MADRS score after follow-up) and nonresponders, with the same conclusion of no significant association ([supplementary Table 1](#sup1){ref-type="supplementary-material"}). Scatterplots ([supplementary Figure 3](#sup4){ref-type="supplementary-material"}) were then used to examine potential associations between MIF/miR-451a and MADRS-S (symptoms) at baseline and follow-up separately. A statistically significant but weak association was found only for MIF and MADRS-S at follow-up (ρ=−0.17; R^2^=0.03).

Discussion {#s18}
==========

This is, to our knowledge, the first study to explore the potential role of plasma MIF and miR-451a in patients with depression, anxiety, or stress and adjustment disorders treated with mindfulness-based therapy or TAU. Our main findings were the following: (1) the levels of MIF were significantly decreased after 8 weeks of treatment in patients, whereas miR-451a levels showed a nonsignificant change; (2) a significant association was found between levels of MIF and miR-451a in patients at baseline as well as between changes in MIF and changes in miR-451a post-treatment; (3) no significant associations were found between the changes in either MIF or miR-451a and improvement of psychiatric symptoms.

It is of note that mindfulness-based therapy or TAU in our study reduced MIF levels. MIF is important in the homeostasis of the host immune response. MIF has been reported to be involved in the pathobiology of depression/anxiety ([@CIT0042]; J. [@CIT0011]). Edwards et al. reported that elevated MIF related to depressive symptoms, a smaller cortisol reactivity to acute stress, and lowered morning cortisol values, indicating that MIF may act as a neuro-immune mediator linking depressive symptoms with inflammation and hypothalamic--pituitary--adrenal axis dysregulation ([@CIT0022]). A previous study also showed that MIF levels were reduced after treatment with antidepressants in patients with depression ([@CIT0017]). However, it is not known whether mindfulness-based therapy or CBT have effect on MIF levels. In the present study, we found that MIF was significantly decreased after psychotherapeutic interventions. In line with our finding, Walsh et al. reported that a 4-week mindfulness-based intervention can reduce salivary IL-6 and TNF-α in women with depressive symptomatology ([@CIT0060]). Furthermore, Moreira et al. found that CBT significantly decreases the serum levels of IL-6 and TNF-α in patients with depressive symptoms ([@CIT0041]). Based on the evidence above, mindfulness treatment/CBT may also seem to have an effect on inflammatory immune response in depression, but the underlying mechanism is not well established.

There is not sufficient evidence to show that pharmacological antidepression treatment affects the miR-451a expression. We found only one study showing that treatment with antidepressants could reverse the stress-induced change of miR-451a expression in rat hippocampus. However, it is not known whether psychotherapeutic interventions can affect plasma levels of MIF or miR-451a in patients with psychiatric disorders. In the present study, we found a nonsignificant change in miR-451a after the treatment. We were unable to identify the exact mechanism behind this however, as most miRNAs regulate their targets at cellular levels. We have quantified the circulating miRNA that may not represent the whole effect of regulation by this miRNA at the cellular level; small changes in the circulating miR-451a may represent large changes in cellular miR-451a levels.

It is well known that miR-451a can directly target MIF and downregulate its expression in the cells ([@CIT0003]; N. [@CIT0032]). The circulating miR-451a is usually secreted from their cells of origin ([@CIT0070]; [@CIT0072]). However, the relation between circulating MIF and miR-451a has never been reported. In the present study, we found that there is a significant inverse association between plasma levels of MIF and miR-451 levels in patients with psychiatric disorders. Our study is the first to evaluate a possible association of MIF with circulating miRNA in patients with psychiatric disorders. Similarly, a recently published study reported another circulating miRNA (miR-939) regulates multiple proinflammatory genes in other disease also ([@CIT0035]). We also in this study show a significant association between the change in MIF levels and the change in miR-451a levels in patients with psychiatric disorders after psychotherapeutic interventions. However, the biological mechanism behind this relationship still needs to be examined. Therefore, in any future studies, it will be of interest to examine the relationship between MIF and miR-451a at cellular level in patients with depression, anxiety, and stress and adjustment disorders ([@CIT0071]) ([@CIT0035]).

We have previously shown that mindfulness therapy and TAU reduced psychiatric symptoms in patients with depression, anxiety, and stress and adjustment disorders ([@CIT0053]). Therefore, we investigated whether the changes in MIF and miR-451a were associated with the improvement in psychiatric symptoms in response to psychotherapeutic interventions. However, we were unable to detect any significant associations between response and MIF or miR-451a. In agreement with our findings, a recent study reported that a mindfulness-based intervention can reduce salivary cytokines although the reduction was not related to the improvement in depressive symptoms ([@CIT0060]). Cattaneo et al also reported that treatment with antidepressants reduced the levels of MIF, but the reduction was not associated with treatment response ([@CIT0017]). Recent evidence shows that the expression levels of proinflammatory and inflammatory cytokines in postmortem brain have a positive relationship with the levels in plasma in patients with depression ([@CIT0044]; [@CIT0037]). However, it is important to note that MIF does not cross the blood brain barrier ([@CIT0002]; J. [@CIT0011]). Therefore, the changes in MIF in the plasma may differ from the changes in the brain. Furthermore, multiple preinflammatory cytokines are involved in the development of depression. It is possible that elevated levels of some of these inflammatory cytokines may not be the consequence of the depression but could be a result of brain dysfunction associated with depression and therefore may not be associated with response to treatment. Therefore, a simple reduction in MIF levels may not be enough to improve the depressive symptoms in response to mindfulness therapy or TAU. Taken together, MIF may not act as an independent predictive biomarker for mindfulness therapy or TAU in the circulation.

Our study has several strengths. We provide evidence that psychotherapeutic interventions may reduce MIF levels in patients with psychiatric disorders. MIF levels and miR-451a levels at baseline as well as changes in levels posttreatment were significantly associated with each other. These findings suggest that miRNA may interact with the inflammatory process linked to the psychotherapeutic interventions in patients with psychiatric disorders. As such, this novel contribution has never been shown in previous studies. Although our findings are promising, several general limitations should be considered. First, we do not have postmortem samples to further confirm our findings. Second, the blood samples used for the assays were frozen between 4 to 8 hours after collection, which may affect our results. However, according to Friebe et al., the cytokine levels in EDTA tubes are not affected if the samples are prepared within 8 hours at room temperature ([@CIT0024]). The time points for both blood collection and plasma isolation were, however, available in our patient samples; the results were adjusted for this time point and the results were not affected. Third, we did not perform separate analyses according to the subtype of psychiatric disorders. However, overlapping symptoms are relatively common among these conditions and the patients were therefore analyzed together. Fourth, our findings cannot be used to guide clinical practice methods at present; it needs to be confirmed in independent cohorts. Moreover, our study did not include patients that did not receive any therapy as a control. It might be possible that the changes in MIF and miR-451a were simply a reflection of variability over time.

In conclusion, our results suggest that 8 weeks of psychotherapeutic interventions can reduce the MIF levels in patients with psychiatric disorders. However, this reduction was not associated with an improvement in psychiatric symptoms in response to the treatment. The association between plasma levels of MIF and miR-451 may relate to the regulatory process occurring at the cellular level, even though the biological mechanisms need to be examined in future studies.
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